市值: $2.882T -1.49%
成交额(24h): $102.5955B -0.51%
  • 市值: $2.882T -1.49%
  • 成交额(24h): $102.5955B -0.51%
  • 恐惧与贪婪指数:
  • 市值: $2.882T -1.49%
加密货币
话题
百科
资讯
加密话题
视频
热门新闻
加密货币
话题
百科
资讯
加密话题
视频
bitcoin
bitcoin

$84577.234968 USD

-1.56%

ethereum
ethereum

$2680.004128 USD

-1.70%

tether
tether

$0.999808 USD

0.02%

bnb
bnb

$765.682454 USD

-1.34%

xrp
xrp

$1.484099 USD

-2.46%

usd-coin
usd-coin

$0.999988 USD

0.00%

solana
solana

$119.429084 USD

-1.45%

tron
tron

$0.335308 USD

0.33%

zcash
zcash

$1313.504956 USD

-4.56%

hyperliquid
hyperliquid

$88.248433 USD

-1.74%

dogecoin
dogecoin

$0.092877 USD

-2.97%

chainlink
chainlink

$14.020892 USD

-2.26%

monero
monero

$548.883836 USD

0.03%

cardano
cardano

$0.244660 USD

-3.58%

unus-sed-leo
unus-sed-leo

$9.010719 USD

0.45%

加密货币新闻

iotaMotion Announces First Use of its iotaSOFT® Insertion System Outside the United States

2025/05/13 23:14

iotaMotion Announces First Use of its iotaSOFT® Insertion System Outside the United States

iotaMotion, Inc., a pioneer in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is currently being applied as part of a pre-market clinical investigation at University Hospital of Zurich, headed by Professor Alexander Huber. This study marks a significant step in expanding access to iotaMotion's innovative technology, which is designed to optimize the precision and safety of cochlear implant surgery.

The iotaSOFT® Insertion System, already commercialized in the United States, offers a unique robotic-assisted approach to inserting electrode arrays used in cochlear implants. The system is designed to provide extremely slow and consistent insertion, which is particularly important for preserving delicate intracochlear structures and enabling optimal positioning of the electrode array. Moreover, the system's advanced capabilities allow for real-time monitoring of ECochG signals, enabling surgeons to make dynamic adjustments to insertion parameters to achieve optimal electrode placement.

"We are thrilled to see the first use of the iotaSOFT® Insertion System outside of the United States at such a prestigious institution as University Hospital of Zurich," stated Mike Lobinsky, President & CEO of iotaMotion. "The team at Zurich has been an exceptional partner, and we look forward to continuing our relationship as we work together to advance cochlear implant care and explore techniques that have never been used in a clinical setting prior to this study."

iotaMotion is committed to expanding the availability of its robotic-assisted systems to surgeons and patients worldwide. The company's mission is to empower surgeons with the tools they need to perform surgery with unmatched precision and control, ultimately leading to better outcomes for patients.

"This collaboration with iotaMotion aligns perfectly with our commitment to pushing the boundaries of hearing health technology and improving the lives of patients with hearing loss," added Professor Huber. "We are honored to be the first center in Europe to introduce this groundbreaking system and contribute to its global launch."

iotaMotion, Inc. is a privately held company headquartered in St. Paul, MN, focused on developing and commercializing robotic-assisted systems for cochlear implant surgery. The company's mission is to revolutionize cochlear implant surgery by harnessing robotic technology to enhance the precision, safety, and effectiveness of surgical procedures.iotaMotion, Inc. is a privately held company headquartered in St. Paul, MN, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT® Insertion System, is designed to provide a slow and consistent electrode array insertion that is designed to preserve delicate intracochlear structures and optimize the insertion for optimal IV stimulation. The system is commercially available in the United States and currently undergoing a pre-market clinical investigation in other global markets. For more information, visit www.iotamotion.com or contact Wade Colburn, Vice President of Marketing and Clinical, at pr@iotamotion.com.

原文来源:yahoo

免责声明:info@kdj.com

所提供的信息并非交易建议。根据本文提供的信息进行的任何投资,kdj.com不承担任何责任。加密货币具有高波动性,强烈建议您深入研究后,谨慎投资!

如您认为本网站上使用的内容侵犯了您的版权,请立即联系我们(info@kdj.com),我们将及时删除。

2026年10月03日 发表的其他文章